Seizures in low- and high-grade gliomas: current management and future outlook

References

• van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J. Neurol. Neurosurg. Psychiatry64, 581–587 (1998).
   PubMed Web of Science ®Google Scholar
• Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology59, S21–S26 (2002).
   PubMed Web of Science ®Google Scholar
• Pasquier B, Peoc’H M, Fabre-Bocquentin B et al. Surgical pathology of drug-resistant partial epilepsy. A 10-year-experience with a series of 327 consecutive resections. Epileptic Disord.4, 99–119 (2002).
   PubMedGoogle Scholar
• Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res.38, 45–52 (2000).
   PubMed Web of Science ®Google Scholar
• Naus CC, Bechberger JF, Caveney S, Wilson JX. Expression of gap junction genes in astrocytes and C6 glioma cells. Neurosci. Lett.126, 33–36 (1991).
   PubMed Web of Science ®Google Scholar
• Haglund MM, Berger MS, Kunkel DD, Franck JE, Ghatan S, Ojemann GA. Changes in g-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J. Neurosurg.77, 209–216 (1992).
   PubMedGoogle Scholar
• Aronica E, Yankaya B, Jansen GH et al. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol. Appl. Neurobiol.27, 223–237 (2001).
   PubMed Web of Science ®Google Scholar
• Stefan H, Scheler G, Hummel C et al. Magnetoencephalography (MEG) predicts focal epileptogenicity in cavernomas. J. Neurol. Neurosurg. Psychiatry75, 1309–1313 (2004).
   PubMedGoogle Scholar
• Bateman DE, Hardy JA, McDermott JR, Parker DS, Edwardson JA. Amino acid neurotransmitter levels in gliomas and their relationship to the incidence of epilepsy. Neurol. Res.10, 112–114 (1988).
   PubMedGoogle Scholar
• Schaller B. Influences of brain tumour-associated pH changes and hypoxia on epileptogenesis. Acta Neurol. Scand.111, 75–83 (2005).
   PubMedGoogle Scholar
• Beaumont A, Whittle IR. The pathogenesis of tumour associated epilepsy. Acta Neurochir. (Wien)142, 1–15 (2000).
   PubMed Web of Science ®Google Scholar
• Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumours: a meta-analysis. Mayo Clin. Proc.79, 1489–1494 (2004).
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumours. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology54, 1886–1893 (2000).
   PubMed Web of Science ®Google Scholar
• Wen PY, Marks PW. Medical management of patients with brain tumours. Curr. Opin. Oncol.14, 299–307 (2002).
   PubMedGoogle Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol.2, 473–481 (2003).
   PubMed Web of Science ®Google Scholar
• Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol.2, 404–409 (2003).
   PubMed Web of Science ®Google Scholar
• Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin. Ther.30, 1385–1407 (2008).
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Supko JG, Batchelor T et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res.9, 2940–2949 (2003).
   PubMed Web of Science ®Google Scholar
• Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitroso-urea–cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann. Oncol.12, 217–219 (2001).
   PubMed Web of Science ®Google Scholar
• Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. Am. J. Med.87, 505–510 (1989).
   PubMed Web of Science ®Google Scholar
• Neef C, de Voogd-van der Straaten. An interaction between cytostatic and anticonvulsant drugs. Clin. Pharmacol. Ther.43, 372–375 (1988).
   PubMed Web of Science ®Google Scholar
• Joerger M, Schellens JH, Beijnen JH. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. Methods Find Exp. Clin. Pharmacol.26, 531–545 (2004).
   PubMedGoogle Scholar
• Johannessen SI, Landmark CJ. Value of therapeutic drug monitoring in epilepsy. Expert Rev. Neurother.8(6), 929–939 (2008).
   PubMedGoogle Scholar
• Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology70, 779–787 (2008).
   PubMed Web of Science ®Google Scholar
• Su YW, Chang M-C, Chang MC et al. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neurooncol.71, 315–318 (2005).
   PubMed Web of Science ®Google Scholar
• Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J. Pediatr. Hematol. Oncol.22, 62–65 (2000).
   PubMed Web of Science ®Google Scholar
• Ko CH, Kong CK, Tse PW. Valproic acid and thrombocytopenia: cross-sectional study. Hong Kong Med. J.7, 15–21 (2001).
   PubMedGoogle Scholar
• Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain125, 22–31 (2002).
   PubMed Web of Science ®Google Scholar
• Calatozzolo C, Gelati M, Ciusani E et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J. Neurooncol.74, 113–121 (2005).
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Blood–brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx2, 86–98 (2005).
   PubMedGoogle Scholar
• Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther.301, 7–14 (2002).
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Does P-glycoprotein play a role in pharmacoresistance to antiepileptic drugs? Epilepsy Behav.3, 493–495 (2002).
   PubMedGoogle Scholar
• Potschka H, Volk HA, Loscher W. Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. Neuroreport15, 1657–1661 (2004).
   PubMed Web of Science ®Google Scholar
• Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther.320, 331–343 (2007).
   PubMed Web of Science ®Google Scholar
• Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumours. Neurology67, S10–S13 (2006).
   PubMedGoogle Scholar
• Relling MV, Pui CH, Sandlund JT et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet356, 285–290 (2000).
   PubMed Web of Science ®Google Scholar
• Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J. Neurooncol.72, 255–260 (2005).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Ballman K, Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology73, 1207–1213 (2009).
   PubMed Web of Science ®Google Scholar
• Motl S, Zhuang Y, Waters CM, Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumours. Clin. Pharmacokinet.45, 871–903 (2006).
   PubMed Web of Science ®Google Scholar
• Tibussek D, Distelmaier F, Schonberger S, Gobel U, Mayatepek E. Antiepileptic treatment in paediatric oncology – an interdisciplinary challenge. Klin. Padiatr.218, 340–349 (2006).
   PubMedGoogle Scholar
• van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol.6, 421–430 (2007).
   PubMed Web of Science ®Google Scholar
• Mintzer S, Mattson RT. Should enzyme-inducing antiepileptic drugs be considered first-line agents? Epilepsia50(Suppl. 8), 42–50 (2009).
   PubMed Web of Science ®Google Scholar
• Kurzwelly D, Herrlinger U, Simon M. Seizures in patients with low-grade gliomas – incidence, pathogenesis, surgical management, and pharmacotherapy. Adv. Tech. Stand. Neurosurg.35, 81–111 (2010).
   PubMedGoogle Scholar
• Johannessen LC, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev. Neurother.10, 119–140 (2010).
   PubMed Web of Science ®Google Scholar
• Karceski S Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion 2005. Epilepsy Behav.7, S1–S64 (2005).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Perucca E, Ryvlin P, Ben Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology68, 402–408 (2007).
   PubMed Web of Science ®Google Scholar
• Perucca E Johannessen S, Johannessen SI. The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? Epileptic Disord.5(Suppl. 1), S17–S26 (2003).
   PubMed Web of Science ®Google Scholar
• Toering ST, Boer K, de Groot M et al. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers. Epilepsia50, 1409–1418 (2009).
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Matagne A, Leclercq K et al. SV2A protein is a broad-spectrum anticonvulsant target, functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology54, 715–720 (2008).
   PubMed Web of Science ®Google Scholar
• Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia48, 2111–2115 (2007).
   PubMed Web of Science ®Google Scholar
• Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res.64, 1–11 (2005).
   PubMed Web of Science ®Google Scholar
• Wagner GL, Wilms EB, Van Donselaar CA, Vecht C. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure12, 585–586 (2003).
   PubMed Web of Science ®Google Scholar
• van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J. Neurol.256, 1519–1526 (2009).
   PubMed Web of Science ®Google Scholar
• Maschio M Zapata TE. Levetiracetam in brain tumour patients. Epilepsia46, 105–106 (2005).
   Google Scholar
• Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumour patients. J. Neurooncol.78, 99–102 (2006).
   PubMed Web of Science ®Google Scholar
• Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology71, 665–669 (2008).
   PubMed Web of Science ®Google Scholar
• Lim DA, Tarapore P, Chang E et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized Phase II pilot study. J. Neurooncol.93, 349–354 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhang Q, Tian L, Xiao J, Stefan H, Zhou D. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav.12, 305–310 (2008).
   PubMed Web of Science ®Google Scholar
• Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure17, 405–421 (2008).
   PubMed Web of Science ®Google Scholar
• Uges JW, van Huizen MD, Engelsman J et al. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. Epilepsia50, 415–421 (2009).
   PubMed Web of Science ®Google Scholar
• Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst. Rev.CD001030 (2000).
   Google Scholar
• Wick W, Menn O, Meisner C et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie28, 391–396 (2005).
   PubMedGoogle Scholar
• Gerstner T, Teich M, Bell N et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia47, 1136–1143 (2006).
   PubMedGoogle Scholar
• Ward MM, Barbaro NM, Laxer KD, Rampil IJ. Preoperative valproate administration does not increase blood loss during temporal lobectomy. Epilepsia37, 98–101 (1996).
   PubMedGoogle Scholar
• Anderson GD, Lin YX, Berge C, Ojemann GA. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J. Neurosurg.87, 252–256 (1997).
   PubMed Web of Science ®Google Scholar
• Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia45, 737–744 (2004).
   PubMed Web of Science ®Google Scholar
• Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol. Cancer Ther.4, 1912–1922 (2005).
   PubMed Web of Science ®Google Scholar
• Tang RF, Faussat AM FAU, Majdak PF et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia18, 1246–1251 (2004).
   PubMed Web of Science ®Google Scholar
• Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin. Neuropharmacol.28, 72–78 (2005).
   PubMed Web of Science ®Google Scholar
• Maschio M, Dinapoli L, Zarabla A. Outcome and tolerability of topiramate in brain tumour associated epilepsy. J. Neurooncol.86, 61–70 (2008).
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia50, 387–397 (2009).
   PubMed Web of Science ®Google Scholar
• Taphoorn MJ. Neurocognitive sequelae in the treatment of low-grade gliomas. Semin. Oncol.30, 45–48 (2003).
   PubMedGoogle Scholar
• Klein M, Engelberts NH, van der Ploeg HM et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann. Neurol.54, 514–520 (2003).
   PubMed Web of Science ®Google Scholar
• Bosma I, Vos MJ, Heimans JJ. The course of neurocognitive functioning in high-grade glioma patients. Neuro. Oncol.9, 53–62 (2007).
   PubMed Web of Science ®Google Scholar
• Luyken C, Blumcke I, Fimmers R et al. The spectrum of long-term epilepsy-associated tumours: long-term seizure and tumour outcome and neurosurgical aspects. Epilepsia44, 822–830 (2003).
   PubMed Web of Science ®Google Scholar
• Cascino GD. Surgical treatment for epilepsy. Epilepsy Res.60, 179–186 (2004).
   PubMed Web of Science ®Google Scholar
• Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology43, 1599–1601 (1993).
   PubMedGoogle Scholar
• Chalifoux R, Elisevich K. Effect of ionizing radiation on partial seizures attributable to malignant cerebral tumours. Stereotact. Funct. Neurosurg.67, 169–182 (1996).
   PubMedGoogle Scholar
• Frenay MP, Fontaine D, Vandenbos F, Lebrun C. First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. Eur. J. Neurol.12, 685–690 (2005).
   PubMed Web of Science ®Google Scholar
• Pace A, Vidiri A, Galie E et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol.14, 1722–1726 (2003).
   PubMed Web of Science ®Google Scholar